Compare General Dynamics Corporation (GD) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Mesoblast Limited — how do they compare? General Dynamics Corporation trades at $366.23 (market cap $98.88B), while Mesoblast Limited trades at $18.78 (market cap $2.31B). The key difference: General Dynamics Corporation is far larger — about 42.8× Mesoblast Limited's market cap, and General Dynamics Corporation pays a 1.74% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GD | MESO | |
|---|---|---|
Market Cap | $98.88B | $2.31B |
Sector | Industrials | Technology |
52-Week High | $376.88 | $20.96 |
52-Week Low | $297.05 | $11.35 |
Enterprise Value | $105.06B | $2.32B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $369.5, down 0.88% on the day, with a bullish technical signal and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $4.10 surpassing the $3.67 expectation. Revenue growth is robust, reaching $52.55B in 2025, while net income margin improved to 8.07%. The stock is supported by a substantial $130.8 billion backlog and a consistent dividend, with the next payment of $1.59 scheduled for August 7, 2026.
The outlook for GD is positive, driven by strong defense spending tailwinds, naval contract dominance, and consistent earnings beats. Investment opportunities include exposure to growing submarine and C5ISR markets. Key risks involve execution on massive backlogs, potential defense budget volatility, and valuation metrics (P/E of 23.01) that are above some industry peers, requiring sustained growth to justify.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
